{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Yttrium_Y_90-Edotreotide",
  "nciThesaurus": {
    "casRegistry": "",
    "chebiId": "",
    "chemicalFormula": "",
    "definition": "A radioconjugate consisting of the octreotide derivative edotreotide labeled with yttrium 90 (Y-90) with potential radiotherapeutic uses. Similar to octreotide, yttrium Y 90-edotreotide binds to somatostatin receptors (SSTRs), especially type 2 receptors, present on the cell membranes of many types of neuroendocrine tumor cells, delivering tissue-specific, beta-emitting nuclide Y-90-mediated cytotoxicity to SSTR-positive cells. Yttrium Y 90-edotreotide is produced by substituting tyrosine for phenylalanine at the 3 position of the somatostatin analogue octreotide and chelating the substituted octreotide to Y-90 via dodecanetetraacetic acid (DOTA).",
    "fdaUniiCode": "ABF7OG3FA3",
    "identifier": "C2601",
    "preferredName": "Yttrium Y 90-Edotreotide",
    "semanticType": "Pharmacologic Substance",
    "subclassOf": [
      "C129819",
      "C2124"
    ],
    "synonyms": [
      "90Y-DOTA-3-Tyr-Octreotide",
      "EDOTREOTIDE YTTRIUM Y-90",
      "OctreoTher",
      "Onalta",
      "Yttrium Y 90 -DOTATOC",
      "Yttrium Y 90 SMT 487",
      "Yttrium Y 90-DOTA-3-tyrosine-octreotide",
      "Yttrium Y 90-DOTA-Tyr3-Octreotide",
      "Yttrium Y 90-Edotreotide",
      "yttrium Y 90 SMT 487",
      "yttrium Y 90 edotreotide",
      "yttrium Y 90-DOTA-tyr3-octreotide"
    ]
  }
}